Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
Samaha et al., Viruses, doi:10.3390/v13060989 (results 1/16)
Samaha et al., Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected.., Viruses, doi:10.3390/v13060989 (results 1/16)
Jan 2021   Source   PDF  
  All Studies   Meta
This study was retracted.
Samaha et al., 16 Jan 2021, peer-reviewed, 16 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: viruses Article Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon Ali A. Samaha 1,2,3,4,† , Hussein Mouawia 1,† , Mirna Fawaz 2 , Hamad Hassan 1,5 , Ali Salami 6 , Ali Al Bazzal 1 , Hamid Bou Saab 7 , Mohamed Al-Wakeel 8 , Ahmad Alsaabi 9 , Mohamad Chouman 1 , Mahmoud Al Moussawi 10 , Hassan Ayoub 4 , Ali Raad 1 , Ola Hajjeh 1 , Ali H. Eid 11,12, * and Houssam Raad 1, * 1 2 3 4 5 6   7 8 9 Citation: Samaha, A.A.; Mouawia, 10 H.; Fawaz, M.; Hassan, H.; Salami, A.; 11 Bazzal, A.A.; Saab, H.B.; Al-Wakeel, 12 M.; Alsaabi, A.; Chouman, M.; et al. * † Effects of a Single Dose of Ivermectin Faculty of Public Health, Lebanese University, Beirut, Lebanon; (A.A.S.); (H.M.); (H.H.); (A.A.B.); (M.C.); (A.R.); (O.H.) Nursing Department, Faculty of Health Sciences, Beirut Arab University, Beirut, Mazraa 1105, Lebanon; Department of Biomedical Sciences, Lebanese International University, Beirut, Mazraa 1105, Lebanon Department of Cardiology, Rayak University Hospital, Bekaa 1801, Lebanon; Ministry of Health, Beirut, Lebanon Department of Mathematics, Faculty of Sciences, Lebanese University, Nabatieh 1700, Lebanon; Faculty of Sciences, Lebanese University, Zahle 1801, Lebanon; Karbala Health Directory, Baghdad 10081, Iraq; Department of Biology, Lille University, 59160 Lille, France; Faculty of Nursing Sciences, Islamic University of Lebanon, Baalbek 1800, Lebanon; Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar Biomedical and Pharmaceutical Unit, QU Health, Qatar University, Doha, Qatar Correspondence: (A.H.E.); (H.R.); Tel.: +974-4403-7893 (A.H.E.) These authors contributed equally to this work. on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon. Viruses 2021, 13, 989. Academic Editors: Kenneth Lundstrom and Alaa A. A. Aljabali Received: 19 March 2021 Accepted: 9 May 2021 Published: 26 May 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Abstract: Objective: This study was designed to determine the efficacy of ivermectin, an FDAapproved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was conducted in 100 asymptomatic Lebanese subjects that have tested positive for SARS-CoV2. Fifty patients received standard preventive treatment, mainly supplements, and the experimental group received a single dose (according to body weight) of ivermectin, in addition to the same supplements the control group received. Results: There was no significant difference (p = 0.06) between Ct-values of the two groups before the regimen was started (day zero), indicating that subjects in both groups had similar viral loads. At 72 h after the regimen started, the increase in Ct-values was dramatically higher in..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop